Literature DB >> 2113003

Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

S Silber1.   

Abstract

Nitrates are highly effective both in terminating acute attacks of angina pectoris and in the prophylaxis of symptomatic and asymptomatic myocardial ischemia. Preload reduction by venodilatation is the prevailing mechanism of nitrates in patients with chronic stable angina and is the unique feature distinguishing them from beta and calcium-channel blockers. Nitrates dilate coronary arteries not only in pre- and poststenotic vessels, but also in eccentric lesions. In patients with endothelial dysfunction, nitrates seem to be the physiological substitute for endothelium-derived relaxing factor. During the past decade, however, there has been substantial evidence of a clinically relevant loss of the anti-ischemic effects ("nitrate tolerance"). Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure. Complete loss of anti-ischemic effects after repetitive, continuous patch attachments has also been found. As we first showed in 1983, intermittent therapy with once-daily ingestion of high-dose sustained-release isosorbide dinitrate was successful in preventing the development of tolerance. Similarly, tolerance to isosorbide-5-mononitrate also does not develop when it is ingested once daily. It is now generally accepted that a daily low-nitrate interval is required to prevent tolerance development. Although the minimal patch-free interval required to prevent tolerance needs further investigation, a 12-h patch-free interval should prevent tolerance in most patients. The prolonged duration of action of once-daily high-dosage administration of sustained-release formulations, the improved patient compliance with a single daily administration, and the increased likelihood of maximal anti-ischemic effects are important reasons for recommending high single daily doses of isosorbide dinitrate or isosorbide-5-mononitrate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113003     DOI: 10.1007/bf01417564

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  239 in total

Review 1.  Antianginal drug therapy for silent myocardial ischemia.

Authors:  W H Frishman; M Teicher
Journal:  Am Heart J       Date:  1987-07       Impact factor: 4.749

2.  Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion.

Authors:  B Stegaru; R Loose; H Keller; J Buss; E Wetzel
Journal:  Am J Cardiol       Date:  1988-03-25       Impact factor: 2.778

3.  Anti-ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once daily or twice daily.

Authors:  S Silber; K H Krause; C Garner; K Theisen; H Jahrmärker
Journal:  Z Kardiol       Date:  1983

4.  Silent myocardial ischemia in patients with a defective anginal warning system.

Authors:  P F Cohn
Journal:  Am J Cardiol       Date:  1980-03       Impact factor: 2.778

5.  Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure.

Authors:  N Sharpe; R Coxon; M Webster; R Luke
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

6.  A preliminary double-blind study of intravenous nitroglycerin in acute myocardial infarction.

Authors:  Y Lis; D Bennett; G Lambert; D Robson
Journal:  Intensive Care Med       Date:  1984       Impact factor: 17.440

7.  Intravenous isosorbide dinitrate in patients with refractory pump failure and acute myocardial infarction.

Authors:  B Rabinowitz; I Tamari; E Elazar; H N Neufeld
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

8.  Resistance to isosorbide dinitrate in patients with severe chronic heart failure: incidence and attempt at hemodynamic prediction.

Authors:  D Kulick; A Roth; N McIntosh; S H Rahimtoola; U Elkayam
Journal:  J Am Coll Cardiol       Date:  1988-10       Impact factor: 24.094

Review 9.  Silent myocardial ischemia.

Authors:  P F Cohn
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

Review 10.  Nitrate tolerance.

Authors:  C V Leier
Journal:  Am Heart J       Date:  1985-07       Impact factor: 4.749

View more
  10 in total

Review 1.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

Review 2.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor.

Authors:  H Bohn; J Brendel; P A Martorana; K Schönafinger
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

4.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

5.  Clinical pharmacological equivalence of a novel FCH-free GTN spray with low ethanol content vs a FCH-containing GTN spray.

Authors:  C de Mey; K Erb; T Zimmermann; H Mutschler; H Blume; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  Optimal medical management of angina.

Authors:  Brian Noronha; Edward Duncan; Jonathan A Byrne
Journal:  Curr Cardiol Rep       Date:  2003-07       Impact factor: 2.931

Review 7.  Nitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgery.

Authors:  Na Zhao; Jin Xu; Balwinder Singh; Xuerong Yu; Taixiang Wu; Yuguang Huang
Journal:  Cochrane Database Syst Rev       Date:  2016-08-04

8.  Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.

Authors:  Bobby Nossaman; Edward Pankey; Philip Kadowitz
Journal:  Crit Care Res Pract       Date:  2012-02-28

Review 9.  Role of short-acting nitroglycerin in the management of ischemic heart disease.

Authors:  William E Boden; Santosh K Padala; Katherine P Cabral; Ivo R Buschmann; Mandeep S Sidhu
Journal:  Drug Des Devel Ther       Date:  2015-08-19       Impact factor: 4.162

Review 10.  Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications.

Authors:  Wilfried Gyselaers
Journal:  J Clin Med       Date:  2019-03-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.